The company has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 ...

Investor risk aversion was identified as the leading constraint on biotech investment, cited by 64% of respondents. In Europe ...

Pharma industry is navigating its biggest drug pricing compliance overhaul since 2006, as CMS’ 2026 Physician Fee Schedule ...

This investment hesitation represents more than financial calculations—it threatens the pipeline of future therapies. “The ...

Prader-Willi syndrome is a rare genetic condition that can present from birth. Its occurrence is around 1 in 15,000, and tens ...

In a recent presentation at the Medicaid Drug Rebate Program Summit, Lorilyn Rosales-Menzel, associate general counsel for US ...

Viatris will acquire all outstanding shares of Pacira's common stock for $36.50 per share, representing an aggregate equity ...

Organizations shift from manual compliance to embedded digital systems with continuous oversight, data integration and ...

Ona Therapeutics CEO discusses next-generation ADC innovation, clinical trends and opportunities at BIO-Europe in Cologne ...

Tarn Brown is a Business Transformation Advisor at Columbus UK, working with organisations across Life Sciences to shape ...

Former SEC enforcer Rebecca Fike warns the new SEC-FDA information-sharing deal will likely trigger more insider trading ...

Partnership aims to improve patient access and adherence through mobile-first engagement platform for life sciences firms ...